title: [Lipoprotein (a) and ischemic heart diseases in patients with type 2 diabetes].
abstract: Lipoprotein (a) is a new independent coronary risk factor, but the role of lipoprotein (a) in type 2 diabetes remains controversial. The objective of this study was to demonstrate the relationship between the level of lipoprotein (a) and the coronary artery diseases (CAD) in type 2 diabetes. Recruitment was carried out in 3 groups of patients: Group 1: 110 control subjects, Group 2: 115 diabetics (D), Group 3: 105 diabetics with CAD (DC). The mean age was, 51 + 7; 52 + 6; 56 + 6 respectively. Total cholesterol, triglyceride, HDL-C, LDL-C, Apo A-I, Apo B and lipoprotein (a) were measured for the patients. The Lp (a) level was significantly higher in the diabetic groups as compared to the controls (p < 0.05), but this level was different between D and DC: 312 + 232 vs 347.8 + (NS). However, when the Lp (a) level is higher than 300 mg/ml, there is a significant difference between DC and D (53% vs 42% p = 0.05). There is no correlation between Lp level and total cholesterol; however, there is a significant variation of Lp (a) level with LDL-C (r = -0.14, P = 0.01). There is a negative correlation between Lp (a) and HDL-C (r = -0.13, p = 0.03), Lp (a) and ApoA-I (r = - 0.11, p = 0.05); but there is a positive correlation between Lp (a) and ApoB (r = 0.14, p = 0.02). Lp(a) level higher than 300 mg/L constitutes a coronary risk factor in type 2 diabetes. This contributes, with the other lipid disorders, to the increase of the coronary risk factors in diabetes.
authors.affiliation: Service de Cardiologie, CHU Monastir, Tunisie.
authors.forename: K
authors.initials: K
authors.lastname: Ben Hamda
authors.forename: A S
authors.initials: AS
authors.lastname: Masmoudi
authors.forename: O
authors.initials: O
authors.lastname: Mandhouj
authors.forename: S
authors.initials: S
authors.lastname: Hammami
authors.forename: N
authors.initials: N
authors.lastname: Attia
authors.forename: M
authors.initials: M
authors.lastname: Smaoui
authors.forename: M A
authors.initials: MA
authors.lastname: Zidi
authors.forename: N
authors.initials: N
authors.lastname: Nabli
authors.forename: R
authors.initials: R
authors.lastname: Chaaba
authors.forename: S
authors.initials: S
authors.lastname: Mahjoub
authors.forename: M
authors.initials: M
authors.lastname: Ben Farhat
authors.forename: M
authors.initials: M
authors.lastname: Hammami
mesh_terms: D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications; D006951:Hyperlipoproteinemias / Q000097:blood / Q000150:complications; D015228:Hypertriglyceridemia / Q000097:blood / Q000150:complications; D016014:Linear Models; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000209:etiology*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood; D014416:Tunisia / Q000453:epidemiology
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D017270:Lipoprotein(a); D014280:Triglycerides; D002784:Cholesterol